Watching
QTRX · Quanterix Corporation
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 9 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A weekly close below $2.50, under the $3.00 consensus analyst target, would end the recovery read. Business conditions: third-quarter 2026 revenue tracking below the $142 million guidance floor, a second guidance cut, or the TIME and high-plex ADC panels missing fourth-quarter shipment.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (in 1 day)
How picks are graded →The thesis
Quanterix's shares still trade ahead of the business. The third-quarter report, expected around 9 November 2026, will show whether the spatial-biology and blood-biomarker launches are turning into revenue. The shares closed at $3.21 on 8 October 2026, still above the $3.00 consensus analyst target, while 2026 revenue guidance stands at a reduced $142–148 million. A weekly close below $2.50 would end the recovery read.
The one new fact since the last update is a regulatory win in China. On 7 October 2026 China's National Medical Products Administration (NMPA) cleared the HD-X and SR-X instruments and four blood tests for neurology biomarkers: p-Tau 217, GFAP, p-Tau 181 and NfL. The clearances run through Quanterix's commercialization partner, Innovita Biological Technology (Clinical Lab Products, 7 October 2026). Neither company disclosed revenue terms or a launch date.
The market did not reward the news. Adjusted daily closes show $3.81 on 5 October 2026, $3.44 on 6 October 2026 and $3.21 on 8 October 2026, so the shares kept falling through the approval. The narrative is maturing: the 7 October 2026 China clearance brought new information, yet buying kept fading. The probability that the shares beat the S&P 500 over the next three months is rated low.
Bullish and bearish views on Quanterix Corporation
The bull case on Quanterix Corporation (QTRX), in brief: China opened a regulated clinical market. The bear case: Guidance was cut by roughly a sixth.
Bull case
- China opened a regulated clinical market. On 7 October 2026 the NMPA cleared two Simoa instruments and four neurology blood tests, including the p-Tau 217 Alzheimer's marker. Innovita plans further NMPA submissions for more Quanterix kits (Clinical Lab Products).
- Spatial content reached commercial release. On 25 September 2026 Quanterix moved its PhenoCode 2.0 Molecular Barcoding Kit to full commercial release. It confirmed fourth-quarter 2026 shipment for its TIME panel, which maps immune cells in tumours, and for its high-plex antibody-drug-conjugate (ADC) panel (company release).
- US payer coverage started in July. The 10 August 2026 results release said Anthem Blue Cross and Blue Shield policies have covered qualifying blood-based biomarker testing since 1 July 2026, including the LucentAD Complete Alzheimer's blood test (Q2 results).
- Guidance assumes no end-market help. Management said on 10 August 2026 that the $142–148 million range assumes no improvement in academic or pharmaceutical demand. If those budgets recover, revenue could come in above the range (Q2 results).
Bear case
- Guidance was cut by roughly a sixth. On 10 August 2026 management lowered 2026 revenue guidance to $142–148 million from $169–174 million and pushed cash-flow breakeven to 2027. Second-quarter revenue was $32.9 million, below the $37.5 million consensus GenomeWeb cited, and the net loss was $48.9 million.
- Management cut its year-end 2026 cash forecast to about $80 million from $100 million.
- Analysts sit below the share price. TD Cowen (11 August 2026) and Canaccord Genuity (17 August 2026) cut their targets to $3.00 from $4.00 with hold ratings. MarketBeat showed a three-analyst consensus target of $3.00 as of 1 October 2026, below the $3.21 close on 8 October 2026.
- China revenue depends on a partner. The 7 October 2026 clearances come through Innovita, and neither company disclosed economics or timing. Any China contribution to 2026 revenue is unquantified.
Price setup
The shares closed at $3.21 on 8 October 2026, 60.2% below the 52-week high of $8.06 and down 17.3% over three months, based on adjusted daily closes. The 14-day relative strength index (RSI), a momentum gauge running from 0 to 100, stood at 53.4. That reading is neutral, neither stretched nor washed out.
The early-October rebound has now fully reversed. The close peaked at $3.81 on 5 October 2026, then fell to $3.44 on 6 October 2026 and $3.21 on 8 October 2026. The $3.00 consensus target is the next reference below the last close. The $2.50 level marks the point where the recovery read ends.
Crowding is low on the observable evidence. No SEC filing showing share issuance or insider selling has appeared since the 16 September 2026 inducement-grant disclosure. The next earnings date falls outside the coming 30 days.
Catalysts, next 30 days
- 13 October 2026 — Quanterix presents at Biomarkers, CDx & Precision Medicine Europe in Basel. This is a promotional event, and no order or revenue disclosure is expected.
- 21 October 2026 — Quanterix spatial-proteomics seminar at Yale School of Medicine. This is scientific outreach, and no financial disclosure is expected.
- ~9 November 2026, est. — Third-quarter 2026 results. The date has not been announced; the prior-year report came on 10 November 2025. This is the first report after the guidance cut and the China clearance, and the first year-on-year comparison in which both periods include Akoya Biosciences. The case turns on it.
- 31 December 2026 — Deadline for the promised fourth-quarter TIME and high-plex ADC panel shipments.
What would change the view
Three business results would break the case: third-quarter revenue running below the pace the $142 million guidance floor requires, a second guidance cut, or a year-end cash forecast below about $80 million. A filing for an at-the-market equity offering would also break it. So would the TIME or high-plex ADC panels missing their fourth-quarter shipment date. On price, a weekly close below $2.50 would end the recovery read.
The read would improve if the third-quarter report showed revenue at or above the top of the $142–148 million range. It would also improve if the company gave measurable spatial-kit orders or a dated commercial launch for the China tests. Any of these would be the first company data supporting a price above the $3.00 consensus target.
What it trades with
Quanterix's revenue depends on academic and pharmaceutical research budgets, so the shares tend to trade with life-science tools names exposed to the same customers. Management tied the 10 August 2026 guidance cut directly to those end markets. The blood-biomarker business also ties the shares to sentiment around Alzheimer's blood testing and payer coverage. Strength across diagnostics names has not lifted Quanterix, whose shares fell 17.3% over the three months to 8 October 2026. The case rests on company-specific results more than on the group.
Notes
- Year-on-year revenue comparisons through Q2 2026 are inflated by the July 2025 Akoya Biosciences acquisition; Q3 2025 was the first quarter to include it.
- Management guides to cash-flow breakeven in 2027 and about $80 million of cash at year-end 2026; operating losses continue to draw down the balance sheet until then.
- The company grants equity awards outside its shareholder-approved plan under Nasdaq Listing Rule 5635(c)(4) when hiring senior staff.
- Clinical sales of Simoa instruments and tests in China run through partner Innovita Biological Technology, and the economics of that arrangement have not been disclosed.
Related · shared themes
ADPT
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies' clonoSEQ test won NCCN and International Myeloma Society backing in September 2026, yet the shares slid to $26.09 by 8 October 2026; the Q3 report, expected around 4 November 2026, shows whether test volume confirms the re-rating.
AZTA
Azenta, Inc.
Azenta's recovery case rests on its 9% June-quarter organic growth repeating and on an $11 million cost-cut plan announced in October; the fiscal fourth-quarter report, expected around 20 November 2026, shows whether revenue and free cash flow confirm it.
CAI
Caris Life Sciences, Inc.
Caris Life Sciences is growing revenue faster than its 27–28% FY2026 guidance implies, though a steep fourth-quarter 2025 comparison narrows the room for a raise; the third-quarter report expected around 4 November 2026 shows whether guidance rises above $1.040 billion.
CDNA
CareDx, Inc.
CareDx's shares have more than doubled in three months on a raised 2026 revenue guide and a higher preliminary Medicare rate for AlloSure; the third-quarter report, expected around 3 November 2026, tests whether revenue stays on track for the $490–500 million guide.
See also · stocks to watch